Guiding Monotherapy with Docetaxel or Atezolizumab via the Tumour Mutation Index in Non-small Cell Lung Cancer Patients

Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the genomic profile of non-small cell lung cancer (NSCLC) without the necessity of tissue biopsy. We aimed to assess the ctDNA sequencing-based tumour mutation index (TMI) model for screening responders (from non-responders) who received monotherapy with docetaxel or atezolizumab.